Last summer we launched a product — Enterprise — that is essential to the future of Endpoints News. Corporate customers can now directly support our future development through paid subscriptions, and get a list of extra benefits and content. If you’d like to support the work, please consider doing so today. (We also have a product for individuals called Insider, which you can read about here.)
The news is this: We want to hit our subscription revenue goals now so we can expand the team, bringing you even better reporting sooner rather than later. It’s just $1,000/year for your entire company no matter the size — and you can see one of the benefits below. Every employee who subscribes to Endpoints News will begin to see this new special email header that demonstrates your company’s support.
Special header employees would see with an Enterprise subscription
This isn’t a plea for donations. With a paid subscription, we’re providing you value and new tools (more on that below) and in exchange we’re charging a price.
To do independent journalism rooted in the style John and I have set out since we launched — 2 years, 3,700 articles and 500 daily newsletters ago — here’s one absolute truth: Readers must directly support the business model. And now your company can.
Give your employees full access to endpoints news
Let’s say your company has 2,000 employees. Perhaps 500 of them visit our website and 50 of them are free email subscribers. For just $1,000/year, you can instantly upgrade all 50 to Enterprise — and then as long as your subscription is current, we’ll automatically flag all new email subscribers from your corporate domain and grant them full access to your firm’s Enterprise license.
All of your employees who subscribe to Endpoints News will see the special header in their newsletter, reminding them of your company’s support of independent journalism. We’ll send them all premium Endpoints content which is exclusive to paid subscribers only. And there’s more. Your employees also get:
Once you subscribe, here’s just a sample of the content everyone at your company will have access to:
What you need to know about this record-setting biotech IPO burst as 5 more crash the party looking for $547M
What are the top 10 corporate VCs in biopharma today? And what do they want to fund — or steer clear of?
… and much more to come
Now is the time to support the work
To the hundreds of amazing companies and individuals who’ve already signed up, thank you — what we do isn’t possible without you.
If you’ve been thinking about it but have put it off, we totally get it. But we need your help this month if we’re to hit the lofty totals that’ll allow us to hire a top-class team and build new products while maintaining our independence.
We’ve designed a really easy form that takes a couple minutes to fill out, and requires a credit card payment at the end. Within 24 hours, usually much sooner, you’ll get an email with a full PDF license. You can see the entire terms and conditions here. All of your employees can start enjoying the benefits of a subscription immediately.
Need help? Now many companies have complicated billing processes and protocols. You can chat with our team during business hours via our upgrade page or Reader Center should you require special assistance. To sign in, you can use a traditional password or click a secure “magic link” that we send to your email on file with us. You can also send an email to firstname.lastname@example.org.
We require a credit card payment but in limited circumstances can invoice your company if there is no alternative.
To begin your company’s paid subscription, click on the button below.
Once again, this is a crucial month for this company. You can directly support our future development, so we can build on the track we’ve laid so far. We’ll have more posts over the month on our programs but we need your support today. Thanks for being part of the Endpoints News community.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,700+ biopharma pros who read Endpoints News by email every day.Free Subscription